CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法治疗结直肠癌的最新进展
英文原题：Recent advances in CAR-T cells therapy for colorectal cancer.
查看英文原题
Recent advances in CAR-T cells therapy for colorectal cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
结直肠癌（CRC）是第三大常见癌症，死亡率高，严重影响人们的生命健康。近年来，过继性CAR-T（CAR-T）细胞疗法在血液系统恶性肿瘤的治疗中显示出良好疗效，但在CRC等实体瘤中仍存在许多问题和挑战。例如，肿瘤免疫抑制微环境、CAR-T 细胞靶向性低、CAR-T 细胞在体内存活时间短、CAR-T 细胞增殖能力有限、CAR-T 细胞不能有效浸润肿瘤等。针对CRC中的这些挑战，人们提出了新的方法，本综述全面概述了CAR-T 细胞疗法在CRC中的现状。
展开英文摘要原文
Colorectal cancer (CRC) is the third most common cancer, with a high mortality rate and a serious impact on people's life and health. In recent years, adoptive chimeric antigen receptor T (CAR-T) cells therapy has shown well efficacy in the treatment of hematological malignancies, but there are still many problems and challenges in solid tumors such as CRC.
For example, the tumor immunosuppressive microenvironment, the low targeting of CAR-T cells, the short time of CAR-T cells in vivo , and the limited proliferation capacity of CAR-T cells, CAR-T cells can not effectively infiltrate into the tumor and so on. New approaches have been proposed to address these challenges in CRC, and this review provides a comprehensive overview of the current state of CAR-T cells therapy in CRC.
论文信息
- 作者
- Qin X、Wu F、Chen C、Li Q
- 单位
- Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36238297 · DOI 10.3389/fimmu.2022.904137
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →